Skip to nav Skip to content
Facebook Twitter LinkedIn Email

CID/JID/OFID Manuscript Review Program

The Infectious Diseases Society of America offers category 1 CME credit for reviewing manuscripts. Only reviews received on time and judged satisfactory by the Editor(s) responsible for the particular manuscript will be eligible for CME credit. We only provide CME credit to reviewers if they request CME credit at the time they complete their review.

The features that contribute most importantly to the quality of manuscript reviews for the Journal include: adherence to reviewer guidelines, specificity and accuracy, completeness, usefulness of recommendations to both editors and authors, tone, internal consistency, and mindfulness of the needs of our readers and the medical community as a whole.

To prepare a high quality review, the reviewer should consider existing evidence when preparing his or her comments. The reviewer should place the current work in the context of existing evidence in the area, describe the unique contributions of the current work, and comment on any inconsistencies of the current work with previous research in your area.

You will be notified via email if your review of the assigned manuscript was completed on time and if it met our criteria for CME credit.

Accreditation Statement

The Infectious Diseases Society of America is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.  IDSA designates each manuscript review for a maximum of 3 AMA PRA Category 1 Credit(s)TM.  Physicians should only claim credit commensurate with the extent of their participation in the activity.  Physicians are eligible for up to 3 CME credits for each manuscript review, up to a total of 15 per year.


Through the manuscript peer review process for CID, JID, or OFID, you should be able to:

  • integrate new discoveries or observations in infectious disease research that can be applied in your work
  • use information resources that improve your ability to treat patients or to conduct research in infectious diseases
  • identify articles that provide relevant, new data about infectious diseases that could result in additional knowledge
  • apply new information that could result in improved healthcare outcomes

Disclosure Information 

In compliance with ACCME’s Standards for Commercial Support of Continuing Medical Education, anyone in a position to influence content is required to disclose any real or apparent conflicts of interest before participating in a CME-accredited educational activity. IDSA, in collaboration with CID, JID and OFID, identifies and resolves all conflicts of interest prior to manuscript reviews.

CID Editors Disclosures 


Robert T. Schooley: Advisory/Consultant: VIR; Stocks/Bonds: Antiva Biosciences; Advisory/Consultant; Stocks/Bonds: CytoDyn; Scientific Advisory Board: Monogram Biosciences, Gilead Sciences.

Deputy Editor

Ferric C. Fang: Advisory/Consultant/Honoraria: BioFire, Cepheid; Advisory/Consultant: ELITech; Supplies for Research Project: Luminex; Research Grant: Cepheid.

Assistant Deputy Editor

Barbara D. Alexander: Advisory/Consultant: Scynexis, Lediant, Cidara, Astellas; Research Grants: Shire, Gilead, Scynexis, Astellas.

Associate Editors

Constance A. Benson: Advisory/Consultant: GlaxoSmithKline, MBio Diagnostics; Research Grant: Gilead Sciences.

Carlos del Rio: Advisory/Consultant: ViiV Healthcare.

Kathryn N. Edwards: Nothing to disclose.

Vance Fowler: Advisory/Consultant/Honoraria: Bayer, Contrafect, Janssen, xBiotech, Arsanis, Moderna, Genentech, Basilea; Polyphor; Cidara, Grant Downing; Actavis; Royalties: Up-to-Date; Advisory/Consultant: Basilea, Debiopharm; Research Grants: Karius / MedImmune, Allergan/Contrafect, Genentech/Basilea; Committee Chair: Novartis.

David N. Fredricks: Patent/copyright/license: BD.

Barbara E. Murray: Advisory/Consultant/Honoraria: Back Bay Life Science Adv; Decibio; Biostrategies Group, Decile.Ten Communications (Cempra Pharmaceuticals), Paratek; Research Grants: Forest/Actavis; Cubist/Merck; Theravance; Royalties: UpToDate, ASM

Peter G. Pappas: Advisory/Consultant: Cidara, Vical, Scynexis; Mayne Pharmaceuticals; Research Grants: Astellas, IMMY, Cidara, Merck

Robin Patel: Advisory/Consultant: Curetis, Qvella, St. Jude, Beckman Coulter; Morgan Stanley; Heraeus Medical GmbH; CORMATRIX; Specific Technologies; Diaxonit; Selux Dx; GenMarkDiagnostics; LBT Innovations; PathoQuest; Genentech; DSMB: Actelion; Royalties: UpToDate; IDBR Course; Research Grants: CD Diagnostics, BioFire, Curetis, Merck, Huchison Biofilm Medical Solutions, Accelerate Diagnostics, Allergan, Medicines Company

David L. Paterson: Advisory/Consultant/Honoraria: Merck, Pfizer, Achaogen, GlaxoSmithKline; Advisory Role: Shionogi; Research Grant: Merck

David A. Pegues: Advisory/Consultant: DaVita/Total Renal Care; Chair, Data Safety Monitoring Board: Seres Pharmaceutical

William A. Petri, Jr: Advisory/Consultant: Perrigo Nutritionals; TechLab

Stephanie N. Taylor; Advisory/Consultant: GlaxoSmithKline; Research Grants: Hologic, GlaxoSmithKline, Becton-Dickinson

David L. Thomas: Advisory/Consultant: Merck; Royalties: Up-to-Date Associate Statistical Editor.

Victor de Gruttola: Advisory/Consultant: Biogen, Baylor, BMS, Daiichi Sankyo, Dynavax, Genocea, Gilead, GSK, Lilly, Merck, Novo Norodisk, Prolong Pharma, Roche, ViiV

JID Editors Conflict of Interest Disclosures


Martin Hirsch: Nothing to disclose

Deputy Editor

David Hooper: Consultant: Macrolide Pharmaceuticals, Shionogi, Melinta Therapeutics, Selux  Diagnostics, Bacterioscan,  Cepheid

Associate Editors

Ann Arvin: Nothing to disclose

Marcel Behr: Nothing to disclose

Raymond Chung: Research Grants: Gilead, BMS, Janssen, Abbvie, Merck, Boehringer Ingelheim; Other: Alnylam

Peter Densen: Personal Fees: Achillion, Ionis

Joseph Kovacs:  Personal Fees: Healthcare Infection Society; Non-financial support: Merck; Other: Matinas, Inc; Patent related to Pneumocystis and IL-2 in HIV infection with royalties paid

Daniel Kuritzkes: Personal Fees: Abivax, Bionor, Bristol-Myers Squibb, CytoDyn, GlaxoSmithKline, ViroStatics, InnaVirVax, Teva, Seres, Roche, Oncolys, United Bio-Pharma; Research grants and personal fees: Gilead, Merck, ViiV, Research grants: Janssen, Palisades Therapeutics

Stuart Levitz: Nothing to disclose

William Schaffner: Personal Fees: Merck, Pfizer, Dynavax, Seqirus, SutroVax, Shionogi

Jane Schwebke, Research Grants and Personal Fees: Hologic, Symbiomix, Scynexis, Toltec Pharmaceuticals, StarPharma; Research grants: BD Diagnostics, Curatek, Viamet, Gage Pharmaceuticals

Frederick Southwick: Nothing to disclose 

Peter Weller: Nothing to disclose

Richard Whitley: Personal Fees: Merck, Glaxo Smith Kline, George Washington University CME Department, American Academy of Pediatrics-South Carolina Chapter; Other: Gilead Sciences, Inc., Kite-A Gilead Company

Statistical Editors

Daniel Caffrey: Nothing to disclose

Michael Hughes: Nothing to disclose

Sarah Walker: Nothing to disclose

OFID (Open Forum Infectious Diseases) Editors Conflict of Interest Disclosures 


Paul Sax: Advisory/Consultant: AbbVie, Gilead; GSK/ViiV; Janssen; Merck

Associate Editors

Jonathan Blum: Nothing to disclose

Johanna Daily: Did not disclose

Kimberly Hanson: Nothing to disclose

Keith Kaye: Advisory/Consultant/Honoraria: Allergan, Bayer, Melinta, Nabriva, Paratek, Shinogi

Merck, Zavante, Xellia; Research Grant: Merck

Jonathan Li: Advisory/Consultant: Merck, Gilead, United Biopharma

Maunank Shah: Patent: Emocha Mobile Health; Advisory/Consultant: Gilead; Research Grant: ViiV Health Care

Abigail Zuger: Nothing to disclose

This website uses cookies

We use cookies to ensure that we give you the best experience on our website. Cookies facilitate the functioning of this site including a member login and personalized experience. Cookies are also used to generate analytics to improve this site as well as enable social media functionality.